Search

Displaying results 881 - 890 of 4588 in total
  1. Drug

    Influenza B virus B/Maryland/15/2016 BX-69A antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14559
    ApprovedInvestigational

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

    Mixtures: FLUZONE High-Dose, FLUZONE High-Dose
  2. Drug

    Eftrenonacog alfa

    go.drugbank.com/drugs/DB11608
    Approved

    Eftrenonacog alfa was developed and marketed as Alprolix for intravenous injection by Biogen. It was first approved by the FDA in March 2014 and later approved by the EMA in May 2016. … It is an X-linked genetic disease caused by mutation of the gene for coagulation protein factor IX (FIX), leading to decreased levels of endogenous factor IX and increased susceptibility to recurrent bleeding

  3. Drug

    Levacetylmethadol

    go.drugbank.com/drugs/DB01227
    ApprovedWithdrawn

    Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well.[L44052,T862]

  4. Drug

    Zolmitriptan

    go.drugbank.com/drugs/DB00315
    ApprovedInvestigational

    [A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. … [A193797] Zolmitriptan was first approved by the FDA for sale by Zeneca Pharmaceuticals under the trade name Zomig® on November 25, 1997.

  5. Drug

    Everolimus

    go.drugbank.com/drugs/DB01590
    ApprovedInvestigational

    Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a simi...

  6. Drug

    Triclabendazole

    go.drugbank.com/drugs/DB12245
    ApprovedInvestigational

    Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. … Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.

  7. Drug

    Tinidazole

    go.drugbank.com/drugs/DB00911
    ApprovedInvestigational

    A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.

  8. Drug

    Baloxavir marboxil

    go.drugbank.com/drugs/DB13997
    ApprovedInvestigational

    [L4779] It was also approved by the European Commission on January 7, 2021.[L45241] … [A251760] Baloxavir marboxil was first globally approved in Japan in February 2018,[A39895] followed by the US approval in October, 2018.

  9. Drug

    Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10794
    ApprovedInvestigationalWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

    Mixtures: FLUZONE High-Dose, FLUZONE High-Dose
  10. Drug

    Ipecac

    go.drugbank.com/drugs/DB13293
    ApprovedWithdrawn

    [L2753] Ipecac was approved by Health Canada as an OTC but all those products are now discontinued.